02146nas a2200145   4500000000100000008004100001260003200042100001200074700001200086245006500098300001200163520178200175022002501957020001801982       2025                            d  bSpringer Nature Switzerland1 aOgwu MC1 aIzah SC00aBiotechnological Innovations for Tropical Disease Management  a237-2623 a<p>Biotechnological innovations are increasingly pivotal in managing tropical diseases, offering novel prevention, diagnosis, and treatment approaches. This chapter focuses on biotechnology for tropical disease management, emphasizing the development of advanced vaccines, biotechnological-based diagnostic tools, and vector control strategies. The progress in vaccine technology, particularly for diseases like malaria, dengue, and neglected tropical diseases (NTDs), is a critical milestone in reducing the disease burden in endemic regions. Ongoing research in vaccine development faces challenges related to distribution, uptake, and socioeconomic barriers, but international collaboration and strengthened healthcare systems will be crucial in overcoming these hurdles. Moreover, genetic engineering techniques, such as CRISPR-Cas9 gene editing and the Sterile Insect Technique, offer promising solutions for vector control, especially in reducing mosquito populations and disease transmission. However, these innovations must be carefully assessed for ecological and ethical concerns before widespread implementation. Additionally, biotechnological advancements in natural product research are unlocking new therapeutic possibilities for tropical diseases. The exploration of bioactive compounds from plants and marine organisms, combined with traditional knowledge, can lead to the development of sustainable treatments. Despite significant progress, challenges such as regulatory hurdles, commercialization barriers, and the need for interdisciplinary collaboration remain. Ultimately, biotechnology holds great potential to revolutionize tropical disease management, provided that ethical considerations, ecological impacts, and equitable access are prioritized.</p>
  a2366-0988, 2366-0996  a9783031826214